Published in Clin Cancer Res on August 01, 2007
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
Tumour macrophages as potential targets of bisphosphonates. J Transl Med (2011) 1.53
Breast cancer in young women. Breast Cancer Res (2010) 1.31
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci (2011) 1.22
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion. Oncotarget (2013) 1.01
Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther (2012) 0.93
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis. PLoS One (2012) 0.91
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer (2012) 0.89
Zoledronic acid in breast cancer: latest findings and interpretations. Ther Adv Med Oncol (2011) 0.87
New therapeutic targets for cancer bone metastasis. Trends Pharmacol Sci (2015) 0.86
Bisphosphonates as antimyeloma drugs. Leukemia (2011) 0.83
Painful boney metastases. Korean J Pain (2013) 0.83
Therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye. J Ophthalmol (2010) 0.83
Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells. J Med Chem (2011) 0.83
Zoledronic acid and angiogenesis. Clin Cancer Res (2007) 0.83
Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal (2011) 0.81
Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model. J Ophthalmic Vis Res (2014) 0.81
Bisphosphonates and cancer: what opportunities from nanotechnology? J Drug Deliv (2013) 0.81
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. Eur J Cancer (2015) 0.80
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer (2014) 0.80
Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. J Exp Clin Cancer Res (2010) 0.80
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials (2015) 0.78
Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid. BMC Cancer (2011) 0.78
The evolving role of zoledronic acid in early breast cancer. Onco Targets Ther (2009) 0.77
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. Oncotarget (2016) 0.77
Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. Int J Clin Oncol (2012) 0.77
The effects of zoledronate on monocyte-derived dendritic cells from melanoma patients differ depending on the clinical stage of the disease. Hum Vaccin Immunother (2014) 0.76
Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy? J Clin Med (2013) 0.76
The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells. Sci Rep (2016) 0.76
Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells. Oncotarget (2016) 0.75
Regulation of VEGF by mevalonate pathway inhibition in breast cancer. J Bone Oncol (2013) 0.75
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. Breast Cancer Res (2015) 0.75
Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients. Clin Sarcoma Res (2016) 0.75
Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy? Ther Adv Med Oncol (2009) 0.75
Dental risk factors for osteonecrosis of the jaws: a CONDOR case-control study. Clin Oral Investig (2012) 0.75
Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg (2016) 0.75
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. Breast Cancer Res (2017) 0.75
Dosing of zoledronic acid with its anti-tumor effects in breast cancer. J Bone Oncol (2015) 0.75
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Oncotarget (2016) 0.75
Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC Cancer (2015) 0.75
Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium. Osteoporos Int (2009) 0.75
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Aprepitant for erlotinib-induced pruritus. N Engl J Med (2010) 2.97
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol (2009) 2.94
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opin Biol Ther (2012) 2.27
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist (2008) 2.22
GPR30 is overexpressed in post-puberal testicular germ cell tumors. Cancer Biol Ther (2011) 2.20
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol (2007) 2.08
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol (2008) 1.99
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol (2012) 1.75
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat (2011) 1.69
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res (2002) 1.66
Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology (2003) 1.65
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther (2010) 1.62
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res (2003) 1.61
EGFR mutational status in penile cancer. Expert Opin Ther Targets (2013) 1.57
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer (2010) 1.56
Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther (2009) 1.55
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biol Ther (2009) 1.50
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res (2012) 1.50
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol (2013) 1.46
Molecular epidemiology and phylogenetic analysis of Hepatitis B virus in a group of migrants in Italy. BMC Infect Dis (2015) 1.44
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
Molecular epidemiology and distribution of serotypes, surface proteins, and antibiotic resistance among group B streptococci in Italy. J Clin Microbiol (2007) 1.44
MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. Cancer Biol Ther (2009) 1.42
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta (2007) 1.38
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol (2011) 1.37
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist (2010) 1.35
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res (2003) 1.34
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 1.33
Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med (2011) 1.33
Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther (2009) 1.32
The biological properties of cetuximab. Crit Rev Oncol Hematol (2008) 1.31
The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J Invest Dermatol (2007) 1.28
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer (2008) 1.27
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer (2006) 1.25
Cetuximab: from bench to bedside. Curr Cancer Drug Targets (2010) 1.24
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol (2003) 1.22
Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg (2003) 1.19
Comparative evaluation of the Vitek-2 Compact and Phoenix systems for rapid identification and antibiotic susceptibility testing directly from blood cultures of Gram-negative and Gram-positive isolates. Diagn Microbiol Infect Dis (2011) 1.18
New treatment approaches in renal cell carcinoma. Anticancer Drugs (2009) 1.17
A novel, multiple drug-resistant, serotype 24F strain of Streptococcus pneumoniae that caused meningitis in patients in Naples, Italy. Clin Infect Dis (2002) 1.17
Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med (2011) 1.17
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother (2008) 1.16
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res (2005) 1.16
The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics (2008) 1.15
Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. Hum Immunol (2004) 1.14
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol (2006) 1.14
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol (2010) 1.14
Insights into airway infections by enterococci: a review. Recent Pat Antiinfect Drug Discov (2012) 1.13
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol (2008) 1.13